Co-Diagnostics, Inc. Products to Be Presented at Fair of Havana 2017
October 31 2017 - 7:30AM
Business Wire
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or
the “Company”), a molecular diagnostics company with a unique,
proprietary platform for the development of diagnostic tests,
announced today that its tests for Zika virus, tuberculosis, and
other diseases will be presented this week at the 35th annual
International Fair of Havana (FIHAV) at the EXPOCUBA fairground in
Havana, Cuba.
According to the conference website, FIHAV is the most important
multi-sector trade fair in Cuba, and is considered among the most
representative of the markets in Latin America and the Caribbean.
The 2017 conference will be held from October 30 to November 4, and
in 2016 participation included 3,800 foreign exhibitors from 73
countries, 25 official delegations from various countries and 85
Chambers of Commerce and organizations promoting trade and
investment, and around 150,000 professional visitors. A licensee of
Co-Diagnostics products will be presenting in a booth to offer
diagnostic solutions to the challenges presented by tropical
diseases and other viruses.
Co-Diagnostics CEO Dwight Egan commented: “It is an incredible
opportunity for Co-Diagnostics tests to be presented to a country
that plays such an important role in the Caribbean region. With a
population of over 11 million, an internationally respected
biotechnology industry, an emphasis on preventive medicine, but a
system in need of access to affordable, contemporary diagnostics,
Cuba also represents a significant market for our products.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that has developed and intends to manufacture
and sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or RNA),
and to sell diagnostic equipment from other manufacturers as
self-contained lab systems.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Readers of this press release
are cautioned not to place undue reliance on any forward-looking
statements. The Company does not undertake any obligation to update
any forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
Disclaimer:
This news release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171031005752/en/
Co-DiagnosticsAndrew Benson, Investor
Relations801-438-1036investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024